Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

Corporate Update

ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at the Scrip Awards 2009

    - In September 2009, ThromboGenics was shortlisted for "Biotech
      Company of the Year" and "Licensing Deal of the Year" at the Scrip
      Awards 2009. The Biotech Company of the Year award recognizes the
      progress and achievement a biotech company has made within the last
      twelve months. The Licensing Deal of the Year award acknowledges the
      achievement of a Company in signing a licensing deal that has both
      monetary and strategic benefits to all parties. The awards ceremony
      will take place on November 18, 2009 in London.

    - In October 2009, ThromboGenics announced that it raised
      EUR0.6 million as the result of the exercise of warrants. 90.000 shares
      were created and are now listed on Euronext Brussels. As a result of
      this exercise of warrants, ThromboGenics has 26.417.789 shares
      outstanding.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB)
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , ... September 03, 2015 , ... ... hamstring tear 18 months ago. Conventional treatment and therapy were not working so ... late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone ...
(Date:9/3/2015)... 2015  StemProtein LLC, a leading manufacturer of ... Stemedica Cell Technologies Inc., announced today that it ... of StemProtein. Silberg will help advance the Company,s ... Cell Factors (SCFs), a significant consumer opportunity. ... and biopharmaceutical industries with substantial executive level experience ...
(Date:9/3/2015)... ... September 03, 2015 , ... If you plan to attend the 27th annual ... will also want to sign up for the tour of Framingham State University's newest ... a walk through of the (8) chemistry teaching labs that are exclusively utilizing ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "DNA Sequencing - ... This report briefly reviews basics of ... their applications. Current large and small sequencers are ... applications of sequencing are described including those for ...
Breaking Biology Technology:UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... N.C. and ROCKVILLE, M.D., June 5 ,Laboratory ... LH ), one,of the world,s leading clinical ... Inc. (Nasdaq: VNDA ), a biopharmaceutical ... clinical-stage product,candidates for central nervous system disorders, ...
... Results of phase I/II study highlighted in oral presentation at ... ... Switzerland, June 5 At the 10th,International Conference on Malignant ... investigator-sponsored clinical trial of,Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the ...
... 4 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... vice president of research and development, is scheduled ... Biotechnology & Medical Technology,Conference on June 12 at ... at the,New York Palace Hotel in New York ...
Cached Biology Technology:LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 2LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 3LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 4LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests 5Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 2Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 3Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma 4Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference 2
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... the human gut adaptively shifts more than a quarter ... diet changes from sugar to complex carbohydrates. , This ... survive rapidly changing nutrient conditions but also helps maintain ... microbial society, according to researchers at Washington University School ...
... Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced ... "Multiplexed Active Biologic Array" by the U.S. Patent and ... of addressing one or more electrodes (or "test sites") ... patent also covers a method for storing the value ...
... owners because of their vibrant colors. But those colors may ... For more than a century, biochemists have known that parrots ... of plumage colors, but their biochemical identity has remained elusive. ... behind the colors of parrots, describing on a molecular level ...
Cached Biology News:Highly adaptable genome in gut bacterium key to intestinal health 2Highly adaptable genome in gut bacterium key to intestinal health 3Nanogen Issued Patent for Electronic Microarray With Memory 2Transport System Smuggles Medicines Into Brain 2Transport System Smuggles Medicines Into Brain 3
Request Info...
...
... System Modules Highly ... directional cloning into advanced ... vectors For ... Cloning Systems, the modules ...
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
Biology Products: